Artem Cherkasov is a Professor at the Faculty of Medicine, University of British Columbia and Senior Scientist at the Vancouver Prostate Centre. Research interests include computer-aided drug discovery (CADD), structure-activity modeling, drug reprofiling, new cancer therapeutics discovery and development of novel CADD tools and applications.
Dr. Cherkasov co-authored more than 200 research papers, 80 patent filings and several prominent book chapters. During his tenure at the UBC, Dr. Cherkasov has been a principal applicant or co-applicant on a number of successful grants totalling over 70M dollars, and licenced 6 drug candidates to big pharma companies (AZ, Roche), major international venture funds (5AM) and spin off companies.
Thus, in 2015, the Androgen Receptor inhibitor developed by Dr. Cherkasov was licensed by Hoffman-LaRoche Company for 142M dollars – a record amount for Canadian academic institutions.
In 2017 Dr. Cherkasov led a group of 10 prominent PIs in a successful 24M application to the Canadian Foundation of Innovation to create a complete ADDUCT (accelerated drug discovery using clinical translation) infrastructure at UBC. The grants completes the UBC cross-discipline drug discovery platform with the latest cryo-EM technology, enhanced protein production and purification capabilities and substantial computational infrastructure providing the cutting-edge CADD and AI support for personalized drug discovery.
Dr. Cherkasov holds a number of other research grants from NSERC, CIHR, Prostate Cancer Canada, Prostate Cancer BC, US Department of Defense, Canadian Cancer Research Institute, and NIH among others.